Application of double filtration plasmapheresis in ABO-incompatible liver transplantation
-
摘要:
目的 观察双重滤过血浆置换(DFPP)清除ABO血型不合肝移植患者血型抗体的效果和安全性。 方法 选取武警总医院2012年1月至2014年12月行ABO血型不合肝移植受者18例,定为血型不合组。术前检测受者的抗A或抗B血型抗体滴度>1∶16者行DFPP;另选取同期符合输血原则的肝移植受者20例作为对照组。观察ABO血型不合肝移植受者应用DFPP的抗体滴度、血液生化指标变化情况,以及并发症发生情况;比较血型不合组和对照组受者的急性排斥反应发生率和病死率。 结果 18例患者中,15例术前抗A或抗B血型抗体滴度>1∶16,行DFPP治疗。与DFPP前相比,DFPP后受者血型抗体滴度平均水平明显下降。血液生化检测发现,纤维蛋白原水平在DFPP后显著下降(P=0.0001)。20例次DFPP中,出现低血压3例次,出血3例次,恶心、呕吐1例次,管路凝血1例次,予对症治疗后好转。经DFPP处理过的血型不合组和对照组的急性排斥反应发生率和病死率比较,差异无统计学意义(均为P>0.05)。 结论 DFPP能安全有效地降低血型抗体水平,减少肝移植术后急性排斥反应发生率,提高移植的成功率。 Abstract:Objective To observe the clinical efficacy and safety of double filtration plasmapheresis (DFPP) in eliminating blood group antibody in ABO-incompatible patients undergoing liver transplantation. Methods Eighteen recipients with ABO-incompatible liver transplantation in the General Hospital of Chinese People's Armed Police from January 2012 to December 2014 were selected in the ABO-incompatibility group. The recipients with an antibody titer of anti-A or anti-B blood group>1∶16 were scheduled to undergo DFPP. Another 20 recipients eligible for blood transfusion were chosen into the control group. The changes in the antibody titer, blood biochemical parameters and the incidence of complications were observed in recipients with ABO-incompatible liver transplantation. The incidence of acute rejection and mortality rate between the ABO incompatibility group and control group were statistically compared. Results Among 18 patients, 15 with an antibody titer of anti-A or anti-B blood group>1∶16 received DFPP. After DFPP, the mean antibody titer was significantly declined. Detection of blood biochemical parameters indicated that the level of fibrinogen was significantly decreased following DFPP (P=0.0001). Among 20 cases receiving DFPP, 3 cases presented with hypotension, 3 with hemorrhage, 1 with nausea and vomiting, and 1 with coagulation in pipeline. All symptoms were alleviated after effective treatment. The incidence of acute rejection and mortality rate did not significantly differ between the ABO-incompatibility group and control group after DFPP (both P>0.05). Conclusion DFPP can safely and effectively reduce the level of blood group antibody, decrease the incidence of acute rejection after liver transplantation and enhance the success rate of liver transplantation. -
表 1 ABO血型不合肝移植受者应用DFPP前后血液生化指标的变化
Table 1. Changes of blood biochemical indexes before and after application of DFPP in liver transplant recipients with ABO-incompatibility(x±s)
指 标 n 分子量(D) DFPP前 DFPP后 P值 血尿素氮(mmol/L) 15 60 6.8±1.2 6.4±2.1 0.4641 丙氨酸转氨酶(U/L) 15 55 000 289±42 279±38 0.4476 总胆红素(μmol/L) 15 58 000 179±34 172±21 0.4488 白蛋白(g/L) 15 66 458 31.5±2.3 30.4±2.5 0.1558 纤维蛋白原(g/L) 15 340 000 212±13 168±19 0.0001 -
[1] 沈中阳,邓永林,郑虹,等.ABO血型不合肝移植治疗急危重症肝病患者的临床疗效分析[J].中华危重病急救医学,2014,26(8):529-533.Shen ZY, Deng YL, Zheng H, et al. Analysis of the curative effect of ABO-incompatible liver transplantation in the treatment in patients with acute severe liver disease[J]. Chin Crit Care Med, 2014,26(8):529-533. [2] 阎冰,李捷,郭文治,等. ABO血型不合肝移植术后急性抗体介导的排斥反应研究进展[J/CD].中华肝脏外科手术学电子杂志,2014,3(2):124-126.Yan B, Li J, Guo WZ, et al. Research progress on antibody mediated rejection after liver transplantation with ABO-incompatibility[J/CD]. Chin J Hepatic Surg(Electr Edit),2014,3(2):124-126. [3] 吴李贤, 叶一农, 何宏亮,等. 血浆置换联合持续性血液透析滤过治疗肝衰竭的疗效分析[J]. 热带医学杂志, 2014, 14(4):481-484. http://www.cnki.com.cn/Article/CJFDTOTAL-RDYZ201404021.htmWu LX, Ye YN, He HL, et al. Effect of plasma exchange combined with continuous hemodiafiltration on the treatment of liver failure[J]. J Trop Med, 2014, 14(4):481-484. http://www.cnki.com.cn/Article/CJFDTOTAL-RDYZ201404021.htm [4] Lumlertgul D, Suteeka Y, Tumpong S, et al. Double filtration plasmapheresis in different diseases in Thailand[J]. Ther Apher Dial,2013,17(1):99-116. doi: 10.1111/tap.2013.17.issue-1 [5] Tanabe K. Double-filtration plasmapheresis[J]. Transplantation, 2007,84(12 Suppl):S30-S32. http://cn.bing.com/academic/profile?id=2033562197&encoded=0&v=paper_preview&mkt=zh-cn [6] Tsai MK, Wu MS, Yang CY, et al. B cells and immunoglobulin in ABO-incompatible renal transplant patients receiving rituximab and double filtration plasmapheresis[J]. J Formos Med Assoc,2015,114(4):353-358. doi: 10.1016/j.jfma.2012.12.012 [7] Thorsen T, Dahlgren US, Aandahl EM, et al. Liver transplantation with deceased ABO-incompatible donors is life-saving but associated with increased risk of rejection and post-transplant complications[J]. Transpl Int,2015,28(7):800-812. doi: 10.1111/tri.12552 [8] Demetris AJ, Zeevi A, O'Leary JG. ABO-compatible liver allograft antibody-mediated rejection: an update[J]. Curr Opin Organ Transplant,2015,20(3):314-324. doi: 10.1097/MOT.0000000000000194 [9] Shen T, Lin BY, Jia JJ, et al. A modified protocol with rituximab and intravenous immunoglobulin in emergent ABO-incompatible liver transplantation for acute liver failure[J]. Hepatobiliary Pancreat Dis Int,2014,13(4):395-401. doi: 10.1016/S1499-3872(14)60268-X [10] Tiwari AK, Pandey P, Aggarwal G, et al. Cascade plasmapheresis (CP) as a preconditioning regime in ABO-incompatible live related donor liver transplants (ABOi-LDLT)[J]. Transplant Res,2014, 3 :17. doi: 10.1186/2047-1440-3-17 [11] 江春平,丁义涛,徐庆祥,等.ABO血型不合供肝在肝移植中的应用[J/CD].实用器官移植电子杂志, 2013, 1 (1):27-30.Jiang CP, Ding YT, Xu QX, et al. Application of liver grafts from ABO incompatible donor[J/CD]. Pract J Organ Transplant (Electr Vers) , 2013, 1 (1):27-30. [12] Kim JM, Kwon CH, Joh JW, et al. ABO-incompatible living donor liver transplantation is suitable in patients without ABO-matched donor[J]. J Hepatol,2013,59(6):1215-1222. doi: 10.1016/j.jhep.2013.07.035 [13] Abe M, Sannomiya A, Koike T, et al. Removal of anti-donor antibody by double-filtration plasmapheresis to prevent chronic rejection in kidney transplantation[J]. Transplant Proc,1998,30(7):3108-3109. doi: 10.1016/S0041-1345(98)00952-X [14] 陈立中, 陈国栋. ABO血型不相容活体肾移植的热点评析[J]. 器官移植, 2013, 4(4):187-190. http://www.organtranspl.com/browse/detail/qkid/65/id/346.htmlChen LZ, Chen GD. ABO-incompatible living donor kidney transplantation[J]. Organ Transplant, 2013, 4(4):187-190. http://www.organtranspl.com/browse/detail/qkid/65/id/346.html [15] Sanada Y, Mizuta K, Urahashi T, et al. Role of apheresis and dialysis in pediatric living donor liver transplantation: a single center retrospective study[J]. Ther Apher Dial,2012,16(4):368-375. doi: 10.1111/tap.2012.16.issue-4 [16] Hanafusa N1, Hamasaki Y, Kawarasaki H, et al. The effect of different apheresis modalities on coagulation factor XIII level during antibody removal in ABO-blood type incompatible living related renal transplantation[J]. Transfus Apher Sci,2013,49(2):254-258. doi: 10.1016/j.transci.2013.06.004
计量
- 文章访问数: 63
- HTML全文浏览量: 98
- PDF下载量: 16
- 被引次数: 0